TrialNature medicine2025

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.

Zuojun Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.